Dopamine-Derived Salsolinol Derivatives as Endogenous Monoamine Oxidase Inhibitors: Occurrence, Metabolism and Function in Human Brains

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 193-204

  Naoi, Makoto ^a,d   Maruyama, Wakako ^b   Nagy, Georgy M ^c  

^a Institute of Physical and Chemical Research   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

Author keywords

Monoamine oxidase inhibitor; Neurotoxin; Parkinson's disease; Prolactin; Salsolinol

Indexed keywords

1,2 DIMETHYL 6,7 DIHYDROXYISOQUINOLINIUM; ACETALDEHYDE; ALDEHYDE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL DERIVATIVE; DOPAMINE; DOPAMINE DERIVATIVE; INDOLEAMINE; ISOQUINOLINE; ISOQUINOLINE DERIVATIVE; METHYLTRANSFERASE; MONOAMINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; OXOACID; SALSOLINOL; SALSOLINOL DERIVATIVE; SALSOLINOL N METHYLTRANSFERASE; SALSOLINOL SYNTHASE; SYNTHETASE; UNCLASSIFIED DRUG;

ADRENERGIC TRANSMISSION; APOPTOSIS; BRAIN; CATALYSIS; CELL DEATH; DOPAMINERGIC NERVE CELL; ENANTIOMER; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; IN SITU HYBRIDIZATION; METHYLATION; MITOCHONDRIAL RESPIRATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; OXIDATION; PARKINSON DISEASE; PICTET SPENGLER REACTION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA; PARKINSONIA;

EID: 0346154811     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00099-8     Document Type: Article

References (62)

1. Akao Y, Nakagawa Y, Maruyama W, Takahashi T, Naoi M. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3. Neurosci Lett 1999;267:153-6.
2. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 2002;82:913-23.
3. Baum SS, Rommelspacher H. Determination of total dopamine, R- and S-alsolinol in human plasma by cyclodextrin bonded-phase liquid chromatography with electrochemical detection. J Chromatogr B: Biomed Appl 1994;660:235-41.
4. Bembenek M, Abell CW, Chrisey LA, Rozwadowska MD, Gessner W, Brossi A. Inhibition of monoamine oxidase A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines. J Med Chem 1990;33:147-52.
5. Cashaw JL, McMurtrey KD, Brown H, Davis VE. Identification of catecholamine derived alkaloids in mammals by gas chromatography and mass spectrometry. J Chromatogr 1974;99:567-73.
6. Cheng BY, Origitano TC, Collins MA. Inhibition of catechol-O-methyltransferase by 6,7-dihydroxy-3,4-dihydroisoquinolines related to dopamine: to dopamine: demonstration using liquid chromatography and a novel substrate for O-methylation. J Neurochem 1987;48:779-86.
7. Cohen G, Collins MA. Alkaloids from catecholamines in adrenal tissue: possible role in alcoholism. Science 1970;167:1749-51.
8. Collins MA. Neuroamine condensations in human subjects. Adv Exp Med Biol 1980;126:87-102.
9. Collins MA, Cashaw JL, Davis VE. Dopamine-derived tetrahydroisoquinoline alkaloids - inhibitors of neuroamine metabolism. Biochem Pharmncol 1973;22:2337-48.
10. Coscia CJ, Burke W, Jamroz G, Lasala JM, McFarlane J, Mitchel J et al. Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-DOPA-treated parkinsonian patients. Nature 1977;249:617-9.
11. Coscia CJ, Burke WJ, Galloway MP, Kosloff AH, Lasala JM, McFarlane J et al. Effects of norlaudanosolinecalboxylic acids on enzymes of catecholamine metabolism. J Pharmacol Exp Ther 1980;212:91-6.
12. Dordain G, Dostert P, Strolin Benedetti M, Rovei V. Tetrahydroisoquinoline derivatives and parkinsonism. In: Tipton KF, Dostert P, Strolin Benedetti M, editors. Monoamine oxidase and diseases. Prospects for therapy with reversible inhibitors. London: Academic Press; 1984. p. 417-26.
13. Dostert P, Strolin Benedetti M, Dordain G, Vernay D. Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar. J Neural Trans [P-D Sect] 1989;1:269-78.
14. Dostert P, Strolin Benedetti M, Bellotti V, Allievi C, Dordain G. Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects. J Neural Trans 1990;81:215-23.
15. Dostert P, Strolin Benedetti M, Dordain G, Vernay D. Urinary elimination of salsolinol enantiomers in alcoholics. J Neural Trans [GenSect] 1991;85:51-9.
16. Freeman ME, Kanyicska B, Lerant A, Nagy GM. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-631.
17. Haber H, Winkler A, Putscher I, Henklein P, Baeger I, Georgi M et al. Plasma and urine salsolinol in humans: effect of acute ethanol intake on the enantiomeric composition of salsolinol. Alcohol Clin Exp Res 1996;20:87-92.
18. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000;97:2875-80.
19. Holtz P, Stock K, Westermann E. Formation of tetrahydropapaveroline from dopamine in vivo. Nature 1964;203:656-8.
20. Homicsko KG, Kertesz I, Radnai B, Toth BE, Tosh G, Fülop F et al. Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat. Neurochem Int 2002;1232:1-8.
21. Langston JW, Ballard P, Tetrud JW, Irvin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
22. Lasala JM, Coscia CJ. Accumulation of a tetrahydroisoquinoline in phenylketonuria. Science 1979;203:283-4.
23. Maruyama W, Nakahara D, Ota M, Takahashi T, Takahashi A, Nagatsu T et al. N-Methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol in rat brains; in vivo microdialysis study. J Neurochem 1992;59:395-400.
24. Maruyama W, Nakahara D, Dostert P, Takahashi T, Naoi M. Naturally-occurring isoquinolines perturb monoamine metabolism in the brain: studies by in vivo microdialysis. J Neural Trans [GenSect] 1993;94:91-102.
25. Maruyama M, Dostert P, Naoi M. Dopamine-derived 1-methyl-6,7-dihydroxy-isoquinolines as hydroxyl radical promoters and scavengers in the rat brain: in vivo and in vitro studies. J Neurochem 1995;64:2635-43.
26. Maruyama W, Abe T, Tohgi H, Dostert P, Naoi M. A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid. Ann Neurol 1996a;40:119-22.
27. Maruyama W, Narabayashi H, Dostert P, Naoi M. Stereospecific occurrence of a parkinsonian-inducing catechol isoquinoline, N-methyl(R)-salsolinol, in the human intraventricular fluid. J Neural Trans 1996b;103:1069-76.
28. Maruyama W, Deng Y, Dostert P, Naoi M. Analysis of endogenous enantiomers of neurotoxins in clinical samples by a multiple-electrode detection system with a chiral column. In: Acworth IN, Naoi M, Parvez H, Parvez S, editors. Coulometric electrode array detectors for HPLC, progress in HPLC-HPCE, vol. 6. Utrecht: VSP; 1997a. p. 339-50.
29. Maruyama W, Naoi M, Kasamatsu T, Hashizume Y, Takahashi T, Kohda K et al. An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 1997b;69:322-9.
30. Maruyama W, Sobue G, Matsubara K, Hashizume Y, Dostert P, Naoi M. A dopaminergic neurotoxin, 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydro-isoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigrostriatal system of the human brain. Neurosci Lett 1997c;223:61-4.
31. Maruyama W, Sango K, Iwasa K, Minami C, Dostert P, Kawai M et al. Dopaminergic neurotoxins, 6,7-dihydroxy-1-(3′,4′ -dihydroxy-benzyl)-isoquinolines, cause different types of cell death in SH-SY5Y cells: apoptosis was induced by oxidized papaverolines and necrosis by reduced tetrahydropapverolines. Neurosci Lett 2000;291:89-92.
32. Maruyama W, Akao Y, Youdim MBH, Davis GA, Naoi M. Transfection-enforced Bcl-2 overexpression and an antiparkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 2001a;78:727-35.
33. Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methyl-propargy-lamine. J Neural Trans 2001b;108:11-24.
34. Matsubara K, Ota M, Takahashi T, Maruyama W, Naoi M. Structural studies of condensation products of biogenic amines as inhibitors of tryptophan hydroxylase. Brain Res 1994;655:121-7.
35. Meyerson LP, McMurtrey KD, Davis VE. Neuroamine-derived alkaloids. Substrate-preferred inhibitors of rat brain monoamine oxidase in vitro. Biochem Phannacol 1976;25:1013-20.
36. Minami M, Takahashi T, Maruyama W, Takahashi A, Dostert P, Nagatsu T et al. Inhibition of tyrosine hydroxylase by R and S enantiomers of salsolinol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoqunoline. J Neurochem 1992;58:2097-101.
37. Minami M, Maruyama W, Dostert P, Nagatsu T, Naoi M. Inhibition of type A and B monoamine oxidase by 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines and their N-methylated derivatives. J Neural Trans [GenSect] 1993;92:125-35.
38. Moser A, Kämpf D. Presence of methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF. Life Sci 1992;50:1885-91.
39. Moser A, Scholz J, Nobbe F, Vieregge P, Böhme V, Bamberg H. Presence of N-methyl-norsalsolinol in the CSF: correlation with dopamine metabolites of patients with Parkinson's disease. J Neurol Sci 1995;131:183-9.
40. Muller T, Sallstrom Baum S, Haussermann P, Przuntek H, Rommelspacher H, Kuhn W. R- and S-salsolinol are not increased in cerebrospinal fluid of parkinsonian patients. J Neurol Sci 1999;164:158-62.
41. Naoi M, Maruyama W, Dostert P. Binding of 1,2(N)-dimethyl-6,7-dihydroxy-isoquinolinium ion to melanin: effects of ferrous and ferric ion on the binding. Neurosci Lett 1994a;171:9-12.
42. Naoi M, Maruyama W, Sasuga S, Deng Y, Dostert P, Ohta S et al. Inhibition of type A monoamine oxidase by 2(N)-methyl-6, 7-dihydrxyisoquinolinium ions. Neurochem Int 1994b;25:475-82.
43. Naoi M, Maruyama W, Zhang JH, Takahashi T, Deng Y, Dostert P. Enzymatic oxidation of the dopaminergic neurotoxin, 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, into 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion. Life Sci 1995;57:1061-6.
44. Naoi M, Maruyama W, Dostert P, Hashizume Y, Nakahara D, Takahashi T et al. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetra-hydroisoqunoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res 1996a;709:285-95.
45. Naoi M, Maruyama W, Dostert P, Kohda K, Kaiya T. A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol. Neurosci Lett 1996b;212:183-6.
46. +-like neurotoxin, 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion, in the substantia nigra of human brains. Neurosci Lett 1997;235:81-4.
47. Naoi M, Maruyama W, Dostert P. An animal model of Parkinson's disease prepared by endogenous N-methyl(R)salsolinol. In: Moser A, editor. Pharmacology of endogenous neurotoxins, a handbook. Boston: Birkhäuser; 1998a. p. 41-61.
48. Naoi M, Maruyama W, Matsubara K, Tipton K, Strolin Benedetti M, Parvez H. Analysis of salsolinols, endogenous neurotoxins, in human materials. In: Qureshi GA, Parvez H, Caudy P, Parvez S, editors. Progress in HPLC-HPCE. Neurochemical markers of degenerative nervous diseases and drug addiction, vol. 7. Utrecht: VSP; 1998b. p. 423-60.
49. Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Strolin Benedetti M. (R)Salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes. Ann Neurol 1998c;43:212-6.
50. Naoi M, Maruyama W, Akao Y, Yi H. Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl (R)salsolinol, and neuro- protection by propargylamines. J Neural Trans 2002;109:607-21.
51. Sandler M, Bonham Carter S, Hunter KR, Stern GM. Tetrahydroisoquinoline alkaloids: in vive metabolites of L-DOPA in man. Nature 1973;241:439-43.
52. Sango K, Maruyama W, Matsubara K, Dostert P, Minami C, Kawai M et al. Enantio-selective occurrence of (S)-tetrahydropapaveroline in human brain. Neurosci Lett 2000;283:224-6.
53. Sjöquist B, Borg S, Kvande H. Salsolinol and methylated salsolinol in urine and cerebrospinal fluid from healthy volunteers. Subst Alcohol Actions Misuse 1981;2:73-7.
54. Storch A, Kaftan A, Burkhardt K, Schwarz J. 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoqunoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism. Brain Res 2000;855:67-75.
55. Strolin Benedetti M, Bellotti V, Pianezzola E, Moro E, Carminati P, Dostert P. Ratio of the R and S enantiomers of salsolinol in food and human urine. J Neural Trans 1989a;77:47-53.
56. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000;166:29-43.
57. Thull U, Kneubühler S, Gaillard P, Carrupt P-A, Testa B, Altomare C et al. Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationship. Biochem Pharmacol 1995;50:869-77.
58. Toth BE, Homicsko K, Radnai B, Maruyama W, Demerit JE, Viceroys M et al. Salsolinol is a putative endogenous neurointermediate lobe prolactin-releasing factor. J Neuroendocrinol 2001;13:1042-50.
59. Ung-Chhun N, Cheng BY, Pronger DA, Serrano P, Chavez C, Perez RF, et al. Alkaloid adducts in human brain: coexistence of 1-carboxylated and noncarboxylated isoquinolines and β-carbolines in alcoholics and nonalcoholics. In: Collins MA, editor. Aldehyde adducts in alcoholism. New York: Alan R. Liss; 1985. p. 125-36.
60. Weiner CD, Collins MA. Tetrahydroisoquinolines derived from catecholamines or DOPA: effects on brain tyrosine hydroxylase activity. Biochem Phannacol 1978;27:2699-703.
61. Willets JM, Lambert DG, Lunec J, Griffiths HR, Phillipson O. Neurotoxicity of 1,2,3,4-tetrahydro-2-methyl-4,6,7-isoquinolinetriol (TMIQ) and effects on catecholamine homeostatis in SH-SY5Y cells. Environ Toxicol Pharmacol 1996;2:59-68.
62. Yamada Y. Effects of salsolinol on rat brain and liver monoamine oxidase. Jpn J Pharmacol 1971;21:833-5.